Swift Biosciences Launches Accel-Amplicon™ Plus Cancer Panels for Precision Medicine Initiatives

New targeted sequencing workflow combines pre-validated content with easy customization and new analysis tools to accelerate variant discovery and screening (ANN ARBOR, Mich. – April 18, 2018) Swift Biosciences today announced the commercial release of its Accel-Amplicon Plus™ Cancer NGS Panels, a suite of nine tumor-specific and focused gene panels to facilitate targeted cancer sequencing. The Accel-Amplicon... Read more

Seegene Will Unveil Combination Test at ECCMID 2018

SEOUL, South Korea, April 17, 2018 /PRNewswire/ — Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies, announced that it will attend the 28th European Congress of Clinical Microbiology and Infectious Diseases (“ECCMID 2018”) taking place in Madrid, Spain, from April 21 to 24, 2018, where it will introduce the “combination test,” which is a high-efficiency solution that diagnoses... Read more

Thermo Fisher Scientific Launches Oncomine Childhood Cancer Research Assay and Establishes International Childhood Oncology Network

Thermo Fisher Scientific Launches Oncomine Childhood Cancer Research Assay and Establishes International Childhood Oncology Network CHICAGO, April 16, 2018 /PRNewswire/ — AACR 2018 — One in 285 children born in the U.S. this year alone will be diagnosed with cancer before their 20th birthday1, yet, until recently, too little was known about the genetic alterations... Read more

GE’s new factory-in-a-box accelerates the production of viral vector based therapeutics

Chalfont St Giles, UK – 17 April 2018 — GE Healthcare is launching a ready-to-run factory-in-a-box to speed up the production of viral vector based therapeutics, including viral vector based vaccines, oncolytic viruses and gene and cell therapies. The new, prefabricated and modular KUBio biomanufacturing facility is designed, constructed, assembled and fully fitted-out to current... Read more

GE’s new factory-in-a-box accelerates the production of viral vector based therapeutics

Chalfont St Giles, UK – 17 April 2018 – GE Healthcare is launching a ready-to-run factory-in-a-box to speed up the production of viral vector based therapeutics, including viral vector based vaccines, oncolytic viruses and gene and cell therapies. The new, prefabricated and modular KUBio https://www.genewsroom.com/press-releases/ges-new-factory-box-accelerates-production-viral-vector-based-therapeutics Read more

RareCyte introduces the CyteFinder® HT instrument at AACR for high throughput slide-based imaging optimized for single cell Liquid Biopsy

SEATTLE, April 16, 2018 /PRNewswire/ — RareCyte, Inc., a global rare cell detection and liquid biopsy company, announces its newest product, CyteFinder HT in conjunction with the American Association for Cancer Research (AACR) Annual Meeting in Chicago April 15 through 18. CyteFinder HT, RareCyte’s newest member of the CyteFinder family, enables high-speed whole slide imaging with up to six channels... Read more

Roche to present new data at AAN highlighting extensive research for OCREVUS and expanding neuroscience pipeline

Basel, 16 April 2018 Roche to present new data at AAN highlighting extensive research for OCREVUS and expanding neuroscience pipeline Breadth of data will reinforce efficacy and safety of OCREVUS in relapsing and primary progressive multiple sclerosis and demonstrate its benefits in slowing disability progression, including new cognitive and biomarker results Important research in Alzheimer’s... Read more

Roche to present new data at AAN highlighting extensive research for OCREVUS and expanding neuroscience pipeline

Basel, 16 April 2018 Roche to present new data at AAN highlighting extensive research for OCREVUS and expanding neuroscience pipeline Breadth of data will reinforce efficacy and safety of OCREVUS in relapsing and primary progressive multiple sclerosis and demonstrate its benefits in slowing disability progression, including new cognitive and biomarker results Important research in Alzheimer’s... Read more

Phenomenex Introduces bioZen Series for Characterization of Biotherapeutics

Torrance, Calif. (April 16, 2018) – Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, introduces bioZen – a new series of LC solutions for bioseparations in pharmaceutical, biopharmaceutical and academic research. The series encompasses both proven and entirely new media spanning two particle platforms – core-shell... Read more